TG Therapeutics (NASDAQ:TGTX) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.63) by 11.11 percent. This is a 1.41 percent increase over losses of $(0.71) per share from the same period last year.
Related Posts
Berner’s Cookies Teams Up With The Flowr Corp. To Bring Its Products To EU Via Portugal
The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF) announced Monday that its indirect wholly-owned subsidiary, RPK Biopharma Ltd, has entered into a series of agreements with Cookies Creative Consulting and Promotions Inc, to cultivate and distribute Cookies products in Portugal from its
Atlantic Equities Downgrades Fiserv to Neutral, Lowers Price Target to $105
Atlantic Equities analyst Kunaal Malde downgrades Fiserv (NASDAQ:FISV) from Overweight to Neutral and lowers the price target from $130 to $105.
Exane BNP Paribas Initiates Coverage On American Axle & Mfg Hldgs with Neutral Rating
Exane BNP Paribas analyst James Picariello initiates coverage on American Axle & Mfg Hldgs (NYSE:AXL) with a Neutral rating.